Barry- Info on the first Pfizer pact from RGEN's last 10-Q
In the fiscal 1997 period, the Company recorded research and
development revenues totaling $257,000, consisting of (1) $65,000 and
$50,000 from Pfizer, Inc. and Glaxo Wellcom plc., respectively for work
performed by the Company's Glycan subsidiary, (2) licensing revenue of
$30,000 from Immunomedics and $50,000 from Neocrin Company, (3)
approximately $36,000 of revenue received from the Partnership for
promotional activities performed by the Company on behalf of the
Partnership's rPF4 program, and (4) $26,000 of other research and
development revenue.
sec.gov
Checked the stock intraday chart.
Stock dropped like a rock at 10:15.
Strange. Maybe someone thought
Pfizer was going to buy the company?
Huge spread in the bid/offer.
Charts at:
lombard.com
Requires registration <free>.
Harvey |
